{"entity":{"id":"henrik-gronberg","kind":"person","name":"Henrik Grönberg","aka":["Henrik Gronberg"],"tldr":"A Stockholm prostate cancer researcher who led the STHLM3 study, which built a blood-and-genetics risk score for deciding which men need a prostate biopsy.","summary":"Henrik Grönberg was first author of the 2015 Lancet Oncology report of STHLM3, a population-based study in Stockholm men aged 50 to 69 that combined PSA, other plasma proteins, 232 genetic markers and clinical details into a single risk score; at the sensitivity of a PSA cutoff of 3 ng/mL it could have reduced biopsies by 32 per cent. Grönberg was a co-author of the STHLM3-MRI screening trial in the New England Journal of Medicine in 2021 and of its two-year follow-up in 2026, and of ALASCCA, the 2025 trial of low-dose aspirin after surgery for colorectal cancer with PI3K pathway alterations. Grönberg's 2026 papers give the affiliations as the Department of Medical Epidemiology and Biostatistics at Karolinska Institutet and the Department of Surgery at Capio S:t Göran's Hospital, and include the protocol of ProBio-mHSPC, a ctDNA-guided platform trial in metastatic hormone-sensitive prostate cancer.","asOf":"2026-11-03","links":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gr%C3%B6nberg%20H%5BAuthor%5D%20AND%20Karolinska%5BAffiliation%5D%20AND%20prostate"}],"tags":[],"related":[],"cancers":["prostate"],"sections":["early-detection"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["karolinska","capio-st-goran"],"pathways":[],"terms":["psa","overdiagnosis"],"trials":["sthlm3-mri","alascca"],"people":[],"bottlenecks":[],"keyPapers":["paper-gronberg-sthlm3-lancet-oncol-2015","paper-eklund-sthlm3-mri-nejm-2021","paper-alascca-n-engl-j-med-2025"],"journals":[],"dependsOn":[],"notes":[],"role":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet; Department of Surgery, Capio S:t Göran's Hospital, Stockholm","institutionId":"karolinska","specialisms":["Prostate cancer screening","Risk prediction","Genetic epidemiology"],"profiles":[{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gr%C3%B6nberg%20H%5BAuthor%5D%20AND%20Karolinska%5BAffiliation%5D%20AND%20prostate"}],"papers":[{"title":"Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study","journal":"Lancet Oncology","year":2015,"doi":"10.1016/S1470-2045(15)00361-7"},{"title":"MRI-targeted or standard biopsy in prostate cancer screening","journal":"New England Journal of Medicine","year":2021,"doi":"10.1056/NEJMoa2100852"},{"title":"Stockholm3-magnetic resonance imaging population-based prostate cancer screening study: two-year follow-up","journal":"Annals of Internal Medicine","year":2026,"doi":"10.7326/ANNALS-25-04753"}]},"route":"/people/henrik-gronberg/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"institution":[{"id":"capio-st-goran","kind":"institution","name":"Capio S:t Göran's Hospital","route":"/institutions/capio-st-goran/"},{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/"}],"term":[{"id":"overdiagnosis","kind":"term","name":"Overdiagnosis","route":"/terms/overdiagnosis/"},{"id":"psa","kind":"term","name":"PSA (prostate-specific antigen)","route":"/terms/psa/"}],"trial":[{"id":"alascca","kind":"trial","name":"ALASCCA","route":"/trials/alascca/"},{"id":"sthlm3-mri","kind":"trial","name":"STHLM3-MRI (Stockholm3 and MRI-targeted biopsy in prostate cancer screening)","route":"/trials/sthlm3-mri/"}],"paper":[{"id":"paper-alascca-n-engl-j-med-2025","kind":"paper","name":"Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer","route":"/key-papers/paper-alascca-n-engl-j-med-2025/"},{"id":"paper-eklund-sthlm3-mri-nejm-2021","kind":"paper","name":"MRI-targeted or standard biopsy in prostate cancer screening (STHLM3-MRI)","route":"/key-papers/paper-eklund-sthlm3-mri-nejm-2021/"},{"id":"paper-gronberg-sthlm3-lancet-oncol-2015","kind":"paper","name":"Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study","route":"/key-papers/paper-gronberg-sthlm3-lancet-oncol-2015/"}]}}